Global Prevalence and Major Risk Factors of Diabetic Retinopathy
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the global prevalence and major risk factors for diabetic retinopathy (DR) and vision-threatening diabetic retinopathy (VTDR) among people with diabetes. RESEARCH DESIGN AND METHODS: A pooled analysis using individual participant data from population-based studies around the world was performed. A systematic literature review was conducted to identify all population-based studies in general populations or individuals with diabetes who had ascertained DR from retinal photographs. Studies provided data for DR end points, including any DR, proliferative DR, diabetic macular edema, and VTDR, and also major systemic risk factors. Pooled prevalence estimates were directly age-standardized to the 2010 World Diabetes Population aged 20–79 years. RESULTS: A total of 35 studies (1980–2008) provided data from 22,896 individuals with diabetes. The overall prevalence was 34.6% (95% CI 34.5–34.8) for any DR, 6.96% (6.87–7.04) for proliferative DR, 6.81% (6.74–6.89) for diabetic macular edema, and 10.2% (10.1–10.3) for VTDR. All DR prevalence end points increased with diabetes duration, hemoglobin A1c, and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes. CONCLUSIONS: There are approximately 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR worldwide. Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated with DR. These data highlight the substantial worldwide public health burden of DR and the importance of modifiable risk factors in its occurrence. This study is limited by data pooled from studies at different time points, with different methodologies and population characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prognosis for retaining vision has improved dramatically over the past 40 years owing to improved metabolic and BP control.78,432,488–490”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [488]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Globally, the overall prevalence of referable DR has been estimated to be around 10%, but this varies across geographic regions, ethnicities, and study methodologies33.”
From Economic evaluation for medical artificial intelligence: accuracy vs. cost-effectiveness in a diabetic retinopathy screening case (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients diagnosed with kidney disease, hypertension, and covered under Medicaid insurance are at higher risk for poor visual outcomes13–24.”
From Autonomous AI-assisted diabetic retinopathy screening at primary care is associated with increased presentation to eye care by at risk patients (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults and early detection is critical for timely management to prevent vision loss1,2.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Artificial intelligence (AI) is an accurate screening tool for diabetic retinopathy (DR), the leading cause of blindness among working-aged adults.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Self-citationColhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · cited 1×
“Statins, however, did not affect DR severity in the few studies in which this was evaluated, although not as a primary outcome (35,36).”
Prevalence of Diabetes among Men and Women in China
Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908292 · Cited by 3,031
Klein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030398010 · Cited by 1,885 · cited 1×
“We showed that the prevalence of DR is substantially higher in type 1 than in type 2 diabetes (11,37), an outcome independent of diabetes duration.”
Self-citationKlein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030405011 · Cited by 1,477 · cited 1×
“If data on age at diagnosis of diabetes were available in these studies, participants were classified as type 1 if they were diagnosed before age 30 years and as type 2 if they were diagnosed with diabetes after age 30 years, as previously used in one study (7).”
Self-citationKlein, R., Klein, B. E. K., Moss, S. E., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)32011-1 · Cited by 1,340
Self-citation
Cited by
Items 201–300 of 1,029
(2023) · doi:10.1002/14651858.cd013775.pub2 · Cited by 145
Zhang, T., Ouyang, H., Mei, X., Lü, B., Yu, Z., Chen, K., Wang, Z., & Ji, L. (2019) · The FASEB Journal · doi:10.1096/fj.201802614rrr · Cited by 150
Prevention of Microvascular Complications of Diabetes
Crasto, W., Patel, V., Davies, M. J., & Khunti, K. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.05.005 · Cited by 167
Interpretable and Fine-Grained Visual Explanations for Convolutional Neural Networks
Wagner, J., Köhler, J. M., Gindele, T., Hetzel, L., Wiedemer, J. T., & Behnke, S. (2019) · 2019 IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR) · doi:10.1109/cvpr.2019.00931 · Cited by 144
Role of microRNAs in the modulation of diabetic retinopathy
Mastropasqua, R., Toto, L., Cipollone, F., Santovito, D., Carpineto, P., & Mastropasqua, L. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.07.003 · Cited by 148
Agardh, E., Lundstig, A., Perfilyev, A., Volkov, P., Freiburghaus, T., Lindholm, E., Rönn, T., Agardh, C.-D., & Ling, C. (2015) · BMC Medicine · doi:10.1186/s12916-015-0421-5 · Cited by 143
“Diabetic retinopathy is a common microvascular complication and, in its severe forms, the leading cause of blindness among working-aged adults in the western world [1].”
InfluentialRecent Advancements in Retinal Vessel Segmentation
Srinidhi, C. L., Aparna, P., & Rajan, J. (2017) · Journal of Medical Systems · doi:10.1007/s10916-017-0719-2 · Cited by 143
“– One of the major landmark study conducted in [1], has”
BackgroundVoigt, M., Schmidt, S., Lehmann, T., Köhler, B., Kloos, C., Voigt, U., Meller, D., Wolf, G., Müller, U. A., & Muller, N. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-120570 · Cited by 160
Vujosevic, S., Muraca, A., Alkabes, M., Villani, E., Cavarzeran, F., Rossetti, L. M., & Cillà, S. D. (2017) · Retina · doi:10.1097/iae.0000000000001990 · Cited by 143
Zhang, J., Qiu, Q., Wang, H., Chen, C., & Luo, D. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112800 · Cited by 149
A Comprehensive Review of Deep Learning Strategies in Retinal Disease Diagnosis Using Fundus Images
Balla, G., Hashmi, M. F., Geem, Z. W., & Bokde, N. D. (2022) · IEEE Access · doi:10.1109/access.2022.3178372 · Cited by 168
“A survey estimates nearly 93 million people worldwide suffer from DR [51].”
BackgroundReactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy
Wilkinson-Berka, J. L., Rana, I., Armani, R., & Agrotis, A. (2013) · Clinical Science · doi:10.1042/cs20120212 · Cited by 141
Hypertensive eye disease: a review
Fraser‐Bell, S., Symes, R. J., & Vaze, A. (2017) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12905 · Cited by 153
“Worldwide, it has been estimated that 93 million people have DR, of which 28 million have sight-threatening disease.(20) DR results from microvascular damage caused by diabetes and has early non-proliferative and late proliferative stages.”
BackgroundChaurasia, S. S., Lim, R. R., Parikh, B. H., Wey, Y. S., Tun, S. B. B., Wong, T. Y., Luu, C. D., Agrawal, R. V., Ghosh, A., Mortellaro, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21198-z · Cited by 148
Self-citationArtificial intelligence for diabetic retinopathy screening, prediction and management
Gunasekeran, D. V., Ting, D. S. W., Tan, G. S. W., & Wong, T. Y. (2020) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000693 · Cited by 133
Self-citationDiabetic choroidopathy: a review of the current literature
Melância, D., Vicente, A., Cunha, J. P., Pinto, L. A., & Ferreira, J. (2016) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-016-3360-8 · Cited by 138
“Diabetic retinopathy (DR) is a leading cause of visual impairment and blindness, affecting almost 35 % of all diabetic patients worldwide [1].”
BackgroundEthnic Differences in the Prevalence and Risk Factors of Diabetic Retinopathy
Tan, G. S. W., Gan, A. T. L., Sabanayagam, C., Tham, Y. C., Neelam, K., Mitchell, P. L. R., Wang, J. J., Lamoureux, E. L., Cheng, C., & Wong, T. Y. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.10.026 · Cited by 153
Self-citationFor the International Retina Group, Busch, C., Zur, D., Fraser‐Bell, S., Laíns, I., Santos, A. R., Lupidi, M., Cagini, C., Gabrielle, P., Couturier, A., et al. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1151-x · Cited by 137
Self-citationNovel imaging biomarkers in diabetic retinopathy and diabetic macular edema
Markan, A., Agarwal, A. K., Arora, A., Bazgain, K., Rana, V., & Gupta, V. (2020) · Therapeutic Advances in Ophthalmology · doi:10.1177/2515841420950513 · Cited by 136
Abnormalities in Glutamate Metabolism and Excitotoxicity in the Retinal Diseases
Ishikawa, M. (2013) · Scientifica · doi:10.1155/2013/528940 · Cited by 154
“Diabetic retinopathy is the most common complication of the diabetes, and a leading cause of visual impairment during the working-age in the industrialized countries [129].”
BackgroundRisk of Blindness Among Patients With Diabetes and Newly Diagnosed Diabetic Retinopathy
Wykoff, C. C., Khurana, R. N., Nguyen, Q. D., Kelly, S. P., Lum, F., Hall, R., Abbass, I. M., Abolian, A. M., Stoilov, I., To, T. M., et al. (2021) · Diabetes Care · doi:10.2337/dc20-0413 · Cited by 127
Im, J. H. B., Jin, Y.-P., Chow, R., & Yan, P. (2022) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2022.01.009 · Cited by 136
Diabetic retinopathy screening in the emerging era of artificial intelligence
Grauslund, J. (2022) · Diabetologia · doi:10.1007/s00125-022-05727-0 · Cited by 146
“…the classification of advanced levels of diabetic retinopathy, which may lead to referral and treatment, it would also be valuable to identify patients without diabetic retinopathy, as they comprise the vast majority of patients [59] and can safely undergo extended screening intervals [60].”
BackgroundSelf-citationSivaprasad, S., & Oyetunde, S. (2016) · Clinical Ophthalmology · doi:10.2147/opth.s100168 · Cited by 134
“5% of patients with diabetes worldwide.(1) Globally, 26.”
Protection of Mcc950 against high-glucose-induced human retinal endothelial cell dysfunction
Zhang, Y., Lv, X., Hu, Z., Ye, X., Zheng, X., Ding, Y., Xie, P., & Liu, Q. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.308 · Cited by 138
“Diabetic retinopathy (DR) is a major diabetic complication that can cause significant visual impairment and blindness.(1,2) During the development of DR, retinal endothelial cell (REC) dysfunction is an important initiator of a multifactorial pathology(3-5) that relies on metabolic abnormalities and inflammation.”
BackgroundXie, J., Ikram, M. K., Cotch, M. F., Klein, B. E. K., Varma, R., Shaw, J. E., Klein, R., Mitchell, P., Lamoureux, E. L., & Wong, T. Y. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.0988 · Cited by 133
Self-citationHeisler, M., Karst, S., Lo, J., Mammo, Z., Yu, T., Warner, S., Maberley, D., Beg, M. F., Navajas, E. V., & Sarunic, M. V. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.2.20 · Cited by 127
Optical Coherence Tomography Angiography in Diabetes and Diabetic Retinopathy
Chua, J., Sim, R. Z. H., Tan, B., Wong, D. W. K., Yao, X., Liu, X., Ting, D. S. W., Schmidl, D., Ang, M., Garhöfer, G., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061723 · Cited by 138
“Approximately a third of the diabetes population has some clinically visible DR, while a further one‐third of those will develop the vision‐threatening state of the disease, characterized by proliferative DR or diabetic macular edema [7].”
BackgroundScreening for Diabetes and Prediabetes
Duan, D., Kengne, A. P., & Echouffo-Tcheugui, J. B. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.05.002 · Cited by 145
Hammes, H.-P., Welp, R., Kempe, H.-P., Wagner, C., Siegel, E., Holl, R. W., & DPV Initiative—German BMBF Competence Network Diabetes Mellitus (2015) · PLOS ONE · doi:10.1371/journal.pone.0132492 · Cited by 131
Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis
Wang, B., Wang, F., Zhang, Y., Zhao, S.-H., Zhao, W., Yan, S., & Wang, Y. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70256-6 · Cited by 142
Diet and risk of diabetic retinopathy: a systematic review
Dow, C., Mancini, F. R., Rajaobelina, K., Boutron‐Ruault, M., Balkau, B., Bonnet, F., & Fagherazzi, G. (2017) · European Journal of Epidemiology · doi:10.1007/s10654-017-0338-8 · Cited by 136
An overview of artificial intelligence in diabetic retinopathy and other ocular diseases
Sheng, B., Chen, X., Li, T., Ma, T., Yang, Y., Bi, L., & Zhang, X. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.971943 · Cited by 123
“In the global finals of intelligent reading of fundus images at the 2018 IEEE International Symposium on Biomedical Imaging (ISBI), the optic disc detection and macular center detection technologies developed independently by researchers won first place worldwide (40).”
BackgroundSelf-citationImaging and Biomarkers in Diabetic Macular Edema and Diabetic Retinopathy
Kwan, C. C., & Fawzi, A. A. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1226-2 · Cited by 141
Plasma Metabonomic Profiling of Diabetic Retinopathy
Chen, L., Cheng, C., Choi, H., Ikram, M. K., Sabanayagam, C., Tan, G. S. W., Tian, D., Zhang, L., Venkatesan, G., Tai, E. S., et al. (2016) · Diabetes · doi:10.2337/db15-0661 · Cited by 141
Self-citationHe, Y., Ren, X., Hu, B., Lam, W., & Li, X. (2018) · BMC Ophthalmology · doi:10.1186/s12886-018-0779-1 · Cited by 129
Diabetic Retinopathy Screening: A Systematic Review on Patients’ Non-Attendance
Kashim, R., Newton, P., & Ojo, O. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15010157 · Cited by 128
Galectin-3: an emerging all-out player in metabolic disorders and their complications
Pugliese, G., Iacobini, C., Pesce, C. M., & Menini, S. (2014) · Glycobiology · doi:10.1093/glycob/cwu111 · Cited by 137
Advances in Retinal Imaging and Applications in Diabetic Retinopathy Screening: A Review
Fenner, B. J., Wong, R. L. M., Lam, W.-C., Tan, G. S. W., & Cheung, G. C. M. (2018) · Ophthalmology and Therapy · doi:10.1007/s40123-018-0153-7 · Cited by 120
Taurine: The comeback of a neutraceutical in the prevention of retinal degenerations
Froger, N., Moutsimilli, L., Cadetti, L., Jammoul, F., Wang, Q., Fan, Y., Gaucher, D., Rosolen, S. G., Neveux, N., Cynober, L., et al. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.03.001 · Cited by 141
An unsupervised coarse-to-fine algorithm for blood vessel segmentation in fundus images
Neto, L. C., Ramalho, G. L. B., Neto, J. F. S. R., Veras, R. D. M. S., & de Medeiros, F. N. S. (2017) · Expert Systems with Applications · doi:10.1016/j.eswa.2017.02.015 · Cited by 134
New insights: A role forO-GlcNAcylation in diabetic complications
Peterson, S. B., & Hart, G. W. (2016) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1135102 · Cited by 134
“Worldwide there are an estimated 93 million people with diabetic retinopathy (Yau et al., 2012) and with the expanding prevalence of diabetes this number is sure to increase.”
BackgroundRashno, A., Koozekanani, D. D., Drayna, P., Nazari, B., Sadri, S., Rabbani, H., & Parhi, K. K. (2017) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2017.2734058 · Cited by 138
“OCT images allow very sensitive detection and quantitative assessment of these fluid cysts and retinal thickening [4], [5].”
BackgroundAdem, K. (2018) · Expert Systems with Applications · doi:10.1016/j.eswa.2018.07.053 · Cited by 125
Peripapillary Microvascular and Neural Changes in Diabetes Mellitus: An OCT-Angiography Study
Vujosevic, S., Muraca, A., Gatti, V., Masoero, L., Brambilla, M., Cannillo, B., Villani, E., Nucci, P., & Cillà, S. D. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-24891 · Cited by 125
“Diabetic retinopathy (DR) is the leading cause of visual impairment in patients with diabetes mellitus (DM).(1) DM affects all cell types in the retina, as reported by numerous experimental and clinical studies.”
BackgroundMan, R. E. K., Sabanayagam, C., Chiang, P. P.-C., Li, L., Noonan, J. E., Wang, J. J., Wong, T. Y., Cheung, C. M. G., Tan, G. S. W., & Lamoureux, E. L. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.5103 · Cited by 132
Self-citationMills, S. A., Jobling, A. I., Dixon, M., Bui, B. V., Vessey, K. A., Phipps, J. A., Greferath, U., Venables, G., Wong, V. H. Y., Wong, C. H. Y., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2112561118 · Cited by 136
Diabetic Complications: Current Challenges and Opportunities
Nickerson, H. D., & Dutta, S. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9388-1 · Cited by 136
“For those with 20 or more years of diabetes, three quarters have some form of diabetic retinopathy [2].”
BackgroundTabrizi, Y. T., Hassanshahi, G., Kounis, N. G., Koniari, I. C., & Khorramdelazad, H. (2019) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-018-00500-8 · Cited by 131
“The report by Rogers et al. also rendered DR as one of the most important causes of blindness in the working-age population of the Western world (Yau et al. 2012).”
BackgroundJee, D., Lee, W. K., & Kang, S. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-12654 · Cited by 119
Unraveling the molecular repertoire of tears as a source of biomarkers: Beyond ocular diseases
Pieragostino, D., D’Alessandro, M., di Ioia, M., Ilio, C. D., Sacchetta, P., & Boccio, P. D. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400084 · Cited by 129
“It is an ocular manifestation of diabetes, a systemic disease, which affects up to 80% of all patients who have had diabetes for 10 years or more [101].”
BackgroundRomero‐Aroca, P., Navarro-Gil, R., Valls, A., Sagarra-Alamo, R., Moreno, A., & Soler-Lluís, N. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-310063 · Cited by 133
Zur, D., Iglicki, M., Sala‐Puigdollers, A., Chhablani, J. K., Lupidi, M., Fraser‐Bell, S., Mendes, T. S., Chaikitmongkol, V., Cebeci, Z., Dollberg, D., et al. (2019) · Acta Ophthalmologica · doi:10.1111/aos.14230 · Cited by 121
Reimagining Healthcare: Unleashing the Power of Artificial Intelligence in Medicine
Iqbal, J., Cortés Jaimes, D. C., Makineni, P., Subramani, S., Hemaida, S., Thugu, T. R., Butt, A. N., Sikto, J. T., Kaur, P., Lak, M. A., et al. (2023) · Cureus · doi:10.7759/cureus.44658 · Cited by 94
“This network comprises multiple processing layers, allowing it to extract meaningful patterns and features from visual data [77].”
BackgroundOxidative Stress, Nox Isoforms and Complications of Diabetes—Potential Targets for Novel Therapies
Sedeek, M. H., Montezano, A. C. I., Hébert, R., Gray, S. P., Marco, E. D., Jha, J. C., Cooper, M. E., Jandeleit-Dahm, K. A. M., Schiffrin, E. L., Wilkinson‐Berka, J. L., et al. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9387-2 · Cited by 128
Detection of Diabetic Retinopathy Using Bichannel Convolutional Neural Network
Pao, S., Lin, H.-Z., Chien, K., Tai, M., Chen, J., & Lin, G. (2020) · Journal of Ophthalmology · doi:10.1155/2020/9139713 · Cited by 135
Prevalence of Diabetic Retinopathy and Blindness in Indonesian Adults With Type 2 Diabetes
Sasongko, M. B., Widyaputri, F., Agni, A. N., Wardhana, F. S., Kotha, S. P., Gupta, P., Widayanti, T. W., Supanji, S., Widyaningrum, R., Wong, T. Y., et al. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.06.019 · Cited by 141
Self-citationSchaal, K. B., Munk, M. R., Wyssmüller, I., Berger, L., Zinkernagel, M. S., & Wolf, S. (2017) · Retina · doi:10.1097/iae.0000000000001938 · Cited by 119
McAvoy, K., Jones, D. S., & Singh, T. R. R. (2018) · Pharmaceutical Research · doi:10.1007/s11095-017-2298-9 · Cited by 124
The innate immune system in diabetic retinopathy
Pan, W. W., Lin, F., & Fort, P. E. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100940 · Cited by 125
Campochiaro, P. A., Khanani, A. M., Singer, M. A., Patel, S. S., Boyer, D. S., Dugel, P. U., Kherani, S., Withers, B., Gambino, L., Peters, K. G., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.04.025 · Cited by 121
Srinivasan, N. K. (2017) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2017/27027.10174 · Cited by 117
Chen, Q., Tang, L., Xin, G., Li, S., Ma, L., Xu, Y., Zhuang, M., Xiong, Q., Wei, Z., Xing, Z., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.419 · Cited by 113
“Diabetic retinopathy (DR) is the leading cause of blindness and severe vision impairment [1].”
BackgroundCurrent management of diabetic tractional retinal detachments
Stewart, M., Browning, D., & Landers, M. B. (2018) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1217_18 · Cited by 118
Hypertension, blood pressure control and diabetic retinopathy in a large population-based study
Liu, L., Quang, N. D., Banu, R., Kumar, H., Tham, Y. C., Cheng, C., Wong, T. Y., & Sabanayagam, C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229665 · Cited by 135
“In 2010, one in three persons with diabetes was estimated to have some form of DR and one in 10 to have vision-threatening DR (VTDR) [2].”
BackgroundSelf-citationChoroidal Thickness in Diabetes and Diabetic Retinopathy: A Swept Source OCT Study
Wang, W., Liu, S., Qiu, Z., He, M., Wang, L., Li, Y., & Huang, W. (2020) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.61.4.29 · Cited by 117
Tu, Y., Song, E., Wang, Z., Ji, N., Zhu, L., Wang, K., Sun, H., Zhang, Y., Zhu, Q., Liu, X., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111274 · Cited by 126
Suo, L., Liu, C., Zhang, Q., Yao, M., Ma, Y., Yao, J., Jiang, Q. L., & Yan, B. (2021) · Theranostics · doi:10.7150/thno.63441 · Cited by 124
“Diabetic retinopathy (DR) is a microvascular complication and is a leading cause of visual disability and blindness in the people with diabetes [8].”
BackgroundNeuroinflammatory responses in diabetic retinopathy
Yu, Y., Chen, H., & Su, S. B. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0368-7 · Cited by 120
“Introduction Diabetic retinopathy (DR) is a common complication of diabetes and a leading cause of legal blindness in workingage adults in the world [1, 2].”
BackgroundLi, S., Yang, H., & Chen, X. (2018) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.18-0146 · Cited by 117
Diabetic Retinopathy: The Role of Mitochondria in the Neural Retina and Microvascular Disease
Miller, D. J., Cascio, M. A., & Rosca, M. G. (2020) · Antioxidants · doi:10.3390/antiox9100905 · Cited by 122
“Diabetic retinopathy (DR) is the leading cause of irreversible visual impairment and blindness in the working-age population [2].”
BackgroundHuang, Y., Wang, Z., Ye, B., Hongjie, J., Ji, S., Sheng, W., Ye, S., Ou, Y., Peng, Y., Xu, Y., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04259-4 · Cited by 124
“The prevalence of any DR endpoint was higher in people with type 1 diabetes (T1D) than in people with type 2 diabetes [1].”
BackgroundArtificial intelligence promotes the diagnosis and screening of diabetic retinopathy
Huang, X., Wang, H., She, C., Feng, J., Liu, X., Hu, X., Chen, L., & Tao, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.946915 · Cited by 115
“The screening tests for DR (usually retinal photography) are safe, simple, acceptable, and bene fi t-validated by many longitudinal studies (3, 4).”
BackgroundModulation of microglia polarization dynamics during diabetic retinopathy in db / db mice
Arroba, A. I., Alcalde‐Estévez, E., García‐Ramírez, M., Cazzoni, D., de la Villa, P., Sánchez‐Fernández, E. M., Mellet, C. O., Fernández, J. M. G., Hernández, C., Simó, R., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.05.024 · Cited by 118
MicroRNAs as biomarkers of diabetic retinopathy and disease progression
Peplow, P., & Martinez, B. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.259602 · Cited by 121
González-Gonzalo, C., Sánchez-Gutiérrez, V., Hernández-Martínez, P., Contreras, I., Lechanteur, Y. T. E., Domanian, A., van Ginneken, B., & Sánchez, C. I. (2019) · Acta Ophthalmologica · doi:10.1111/aos.14306 · Cited by 118
de Vries, V. A., Bassil, F. L., & Ramdas, W. D. (2020) · Scientific Reports · doi:10.1038/s41598-020-70269-7 · Cited by 116
Epidemiological issues in diabetic retinopathy
Scanlon, P. H., Aldington, S. J., & STRATTON, I. M. (2013) · Middle East African Journal of Ophthalmology · doi:10.4103/0974-9233.120007 · Cited by 136
Diabetic retinopathy management guidelines
Chakrabarti, R., Harper, C. A., & Keeffe, J. E. (2012) · Expert Review of Ophthalmology · doi:10.1586/eop.12.52 · Cited by 112
Kiss, S., Liu, Y., Brown, J., Holekamp, N., Almony, A., Campbell, J., & Kowalski, J. (2014) · Clinical Ophthalmology · doi:10.2147/opth.s60893 · Cited by 111
“4 million and 21 million people worldwide, respectively.(5,6) Although the pathogeneses of CRVO, BRVO, and DME are multifactorial, upregulation of VEGF is a common underlying source of vision loss in all three diseases.”
Self-citationChallenges in Elucidating the Genetics of Diabetic Retinopathy
Kuo, J. Z.-C., Wong, T. Y., & Rotter, J. I. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.5024 · Cited by 125
Self-citationRetinal Microaneurysms Detection Using Local Convergence Index Features
Dashtbozorg, B., Zhang, J., Huang, F., & Romeny, B. M. T. H. (2018) · IEEE Transactions on Image Processing · doi:10.1109/tip.2018.2815345 · Cited by 112
“Chronically high blood sugar levels from diabetes are associated with increasing damage to the tiny blood vessels in the retina, leading to diabetic retinopathy [2].”
BackgroundPatient-Driven Diabetes Care of the Future in the Technology Era
Ashrafzadeh, S., & Hamdy, O. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.09.005 · Cited by 111
Voleti, V. B., & Hubschman, J. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.01.018 · Cited by 122
Molecular Mechanisms of Glucose Fluctuations on Diabetic Complications
Zhang, Z., Miao, L.-F., Qian, L., Wang, N., Qi, M., Zhang, Y., Dang, S., Wu, Y., & Wang, R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00640 · Cited by 119
“Diabetic retinopathy (DR) is a microvascular complication, which is considered as one of the main causes of visual impairment and blindness (17).”
BackgroundSelf-citationAnti-VEGF crunch syndrome in proliferative diabetic retinopathy: A review
Tan, Y., Fukutomi, A., Sun, M. T., Durkin, S. R., Gilhotra, J. S., & Chan, W. O. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2021.03.001 · Cited by 122
Comparison Among Methods of Retinopathy Assessment (CAMRA) Study
Ryan, M. E., Rajalakshmi, R., Prathiba, V., Anjana, R. M., Ranjani, H., Narayan, K. M. V., Olsen, T. W., Mohan, V., Ward, L. A., Lynn, M. J., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.06.011 · Cited by 107
Miwa, Y., Murakami, T., Suzuma, K., Uji, A., Yoshitake, S., Fujimoto, M., Yoshitake, T., Tamura, Y., & Yoshimura, N. (2016) · Scientific Reports · doi:10.1038/srep29064 · Cited by 110
Current Treatments for Diabetic Macular Edema
Tatsumi, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119591 · Cited by 114
Liu, X., Li, Y., Li, L., Zhang, L., Ren, Y., Zhou, H., Cui, L., Mao, Z., Hu, D., & Wang, C. (2016) · Scientific Reports · doi:10.1038/srep31426 · Cited by 122
“There are many complications of diabetes such as diabetic eye disease and diabetic nephropathy, which could lead to blindness and kidney failure 5–7 .”
Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy
Bolinger, M. T., & Antonetti, D. A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091498 · Cited by 114
“4 million people with DR that is considered to be a threat to vision [6].”
BackgroundWu, J.-H., Liu, T. Y. A., Hsu, W.-T., Ho, J. H.-C., & Lee, C.-C. (2021) · Journal of Medical Internet Research · doi:10.2196/23863 · Cited by 108
“A meta-analysis estimated global prevalence of any DR and proliferative diabetic retinopathy (PDR) among patients with diabetes to be 35.4% and 7.5%, respectively [2].”
BackgroundInfluentialAl‐Rubeaan, K., Abu El‐Asrar, A. M., Youssef, A. M., Subhani, S. N., Ahmad, N. A., Al‐Sharqawi, A. H., Alguwaihes, A., Alotaibi, M. S., Al‐Ghamdi, A., & Ibrahim, H. M. (2015) · Acta Ophthalmologica · doi:10.1111/aos.12532 · Cited by 108
“When comparing our finding with data from population-based studies in different ethnic groups, retinopathy prevalence in our cohort was similar to the figure reported among Asians representing 20.8%, but lower than Caucasian and African Americans at 46.7% and 55.7%, respectively (Yau et al. 2012).”
BackgroundResultInfluentialOptical Coherence Tomography Angiography in Diabetes
Lee, J. H., & Rosen, R. B. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0811-x · Cited by 108
Holekamp, N. M., Campbell, J. H., Almony, A., Ingraham, H. J., Marks, S. J., Chandwani, H. S., Cole, A. L., & Kiss, S. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.04.010 · Cited by 108
Review of retinal cameras for global coverage of diabetic retinopathy screening
Rajalakshmi, R., Prathiba, V., Arulmalar, S., & Usha, M. (2020) · Eye · doi:10.1038/s41433-020-01262-7 · Cited by 117
“the people with diabetes have some form of DR, this would translate to ~193 million people with some stage of DR by the year 2030 [2].”
BackgroundMale–Female Differences in Diabetic Retinopathy?
Ozawa, G. Y., Bearse, M. A., & Adams, A. J. (2014) · Current Eye Research · doi:10.3109/02713683.2014.958500 · Cited by 120
“6%.(40) Classification of diabetic retinopathy involves two main stages: nonproliferative diabetic FIGURE 2 Male:female ratio among German and Austrian patients diagnosed with type 2 diabetes in different age categories.”
Background[WITHDRAWN] Retinal Vasculature in Development and Diseases
Sun, Y., & Smith, L. E. H. (2018) · Annual Review of Vision Science · doi:10.1146/annurev-vision-091517-034018 · Cited by 122
RetractedThe therapeutic potential of apelin in kidney disease
Chapman, F. A., Nyimanu, D., Maguire, J. J., Davenport, A. P., Newby, D. E., & Dhaun, N. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00461-z · Cited by 114
The eye as a complement dysregulation hotspot
Clark, S. J., & Bishop, P. N. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0649-6 · Cited by 103
“Diabetic retinopathy is a leading cause of preventable blindness around the world; about one-third of the diabetic population suffers from some stage of retinopathy [18].”
Background
Metadata
- Authors
- Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., Haffner, S., Hamman, R. F., Ikram, M. K., Kayama, T., Klein, B. E. K., Klein, R., Krishnaiah, S., Mayurasakorn, K., O’Hare, J. P., Orchard, T. J., Porta, M., Rema, M., Roy, M. S., Sharma, T., Shaw, J., Taylor, H., Tielsch, J. M., Varma, R., Wang, J. J., Wang, N., West, S., Xu, L., Yasuda, M., Zhang, X., Mitchell, P., Wong, T. Y., & for the Meta-Analysis for Eye Disease (META-EYE) Study Group
- Affiliations
- The University of Melbourne (AU)
- Allergan (United States) (US)
- Aarhus University Hospital (DK)
- Taipei Veterans General Hospital (TW)
- Amsterdam Public Health (NL)
- London School of Hygiene & Tropical Medicine (GB)
- Odense University Hospital (DK)
- Shavano Park, Texas
- Colorado School of Public Health (US)
- Erasmus MC (NL)
- Yamagata University (JP)
- University of Wisconsin–Madison (US)
- L V Prasad Eye Institute (IN)
- Samut Sakhon Hospital (TH)
- University of Warwick (GB)
- University of Pittsburgh (US)
- University of Turin (IT)
- Madras Diabetes Research Foundation (IN)
- Rutgers New Jersey Medical School (US)
- Sankara Nethralaya (IN)
- Baker Heart and Diabetes Institute (AU)
- Johns Hopkins University (US)
- University of Southern California (US)
- The University of Sydney (AU)
- Beijing Tongren Hospital (CN)
- Johns Hopkins Hospital (US)
- Kyushu University (JP)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Wong, Tien Y.
- ORCID
- Rogers, Sophie L.
- Kawasaki, Ryo
- Lamoureux, Ecosse L.
- Bek, Toke
- Chen, Shih-Jen
- Fletcher, Astrid
- Grauslund, Jakob
- Hamman, Richard F.
- Ikram, M. Kamran
- Klein, Barbara E.K.
- Klein, Ronald
- Krishnaiah, Sannapaneni
- Mayurasakorn, Korapat
- Orchard, Trevor J.
- Porta, Massimo
- Sharma, Tarun
- Shaw, Jonathan
- Taylor, Hugh
- Tielsch, James M.
- Varma, Rohit
- Wang, Jie Jin
- West, Sheila
- Xu, Liang
- Zhang, Xinzhi
- Mitchell, Paul
- Wong, Tien Y.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-02-10
- Volume
- 35
- Issue
- 3
- Pages
- 556-564
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3322721
- OpenAlex
- W2138480916
- Cited by
- 4,985
- References
- 38
- Citations by year
- 2026: 374 · 2025: 447 · 2024: 477 · 2023: 429 · 2022: 499 · 2021: 544 · 2020: 520 · 2019: 365 · 2018: 331 · 2017: 305 · 2016: 238 · 2015: 198 · 2014: 139 · 2013: 80 · 2012: 30
- FWCI
- 21.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by-nc-nd)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- National University of Singapore (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Research to Prevent Blindness
- Hyderabad Eye Research Foundation
- Oogfonds
- Algemene Nederlandse Vereniging ter voorkoming van Blindheid
- National Institutes of Health
- Allergan
- Medical Research Council
- National Eye Institute (EY0-6594, R01 EY 09860, R01EY009860, U10EY006594, R01EY016379)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic retinopathy, vision-threatening diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, global prevalence, risk factors, diabetes duration, glycemic control, HbA1c, blood pressure, type 1 diabetes, type 2 diabetes, fundus images, public health burden
- MeSH terms
- Adult, Aged, Blood Glucose, Blood Pressure, Diabetic Retinopathy, Female, Humans, Male, Middle Aged, Risk Factors, Prevalence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.